<DOC>
	<DOCNO>NCT00915772</DOCNO>
	<brief_summary>A phase III randomise , double-blind parallel group extension study investigate efficacy safety twice daily administration free combination linagliptin 2.5 mg + metformin 500 mg linagliptin 2.5 mg + metformin 1000 mg versus monotherapy metformin 1000 mg twice daily 54 week type 2 diabetic patient previously complete double-blind part study 1218.46</brief_summary>
	<brief_title>Treatment Type 2 Diabetes With Linagliptin 2.5 mg Bid + Metformin 500 1000 mg Bid Metformin 1000 mg Bid</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Inclusion criterion : Signed date write informed consent , late date Visit 1 Patients complete entire treatment period doubleblind study 1218.46 , treat rescue medication ( Visit 7 ) Exclusion criterion : Patients meet one withdrawal criterion treatment period previous study 1218.46 Premenopausal woman ( last menstruation equal less 1 year prior sign informed consent ) : nursing pregnant , childbearing potential practicing acceptable method birth control , plan continue use method throughout study agree submit periodic pregnancy test participation trial . Acceptable method birth control include transdermal patch , intra uterine devices/systems ( IUDs/IUSs ) , oral , implantable injectable contraceptive , sexual abstinence vasectomise partner addition male partner barrier method , use condom spermicide . No exception make . Alcohol abuse within 3 month prior inform consent would interfere study participation Drug abuse opinion investigator would interfere trial participation Any clinical condition , opinion investigator , would allow safe completion protocol safe administration study medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>